Patent ID: 8975399
Filing Date: 2015-03-10
Classification: A61K,A61P,C07C,C07D,Y02A

Abstract:
1. A method for inactivating TNF-alpha to treat a non-cancer pathology linked to an excessive effect of TNF-alpha, comprising administering to a patient in need thereof: (i) a sulphonated compound of formula I in which • R1 represents R4 represents a hydrogen atom or a C1-C5 alkyl and R3 represents an organic group, said organic group comprising 11 or more than H and containing from 6 to 30 carbon atoms including one or more rings or heterocycles, saturated or unsaturated, fused or not, unsubstituted or substituted by one or more substituents chosen from the C1-C5 alkyl, C1-C5 alkenyl, halo, C3-C8 cycloalkyl, C1-C5 alkoxy, C1-C5 alkylthio, C1-C5 alkylsulphonyl, acyl, hydroxy, NH2, nitro, C1-C5 alkylamino, di(C1-C5 alkyl)amino, acylamino radicals, said organic group not being linked to the carboxyl by a —NH—CH2— group or by a —NH—CH-alk-group where alk represent an alkyl radical with 1 to 5 carbon atoms, said organic group not comprising a  group in which m represents 0, 1 or 2, a, b and c represent CR, where each R represents independently a hydrogen or a C1-C4 alkyl, R1 represents a C1-C4 alkyl or a C3-C7 cycloalkyl, said organic group not comprising a —CO—NHOH group, said organic group not representing a  group in which n=1 or 2 and R1 represents H, halogen, CN, lower alkyl or alkoxy, optionally substituted by a halogen, • R2 represents • X represents a hydrogen atom or one or more substituents chosen from the C1-C5 alkyl, C1-C5 alkoxy, C1-C5 alkenyl, halo, C3-C8 cycloalkyl, C1-C5 alkylthio, C1-C5 alkylsulphonyl, acyl, hydroxy, NH2, nitro, C1-C6 alkylamino, di(C1-C6 alkyl)amino, acylamino radicals, it being understood that X is not a 3,4-dialkoxy or a 3,4-dialkylthio, (ii) a compound of formula I below for which R2=H: the compound for which the compound for which the compound for which the compound for which the compound for which or (iii) 3-(3-phenoxyphenyl)-2-(phenylsulphonyl)—N—(3-pyridinylmethyl) acrylamide, or an addition salt of (i), (ii) or (iii) with pharmaceutically acceptable acid it being understood that